<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03803631</url>
  </required_header>
  <id_info>
    <org_study_id>COCTAEyl</org_study_id>
    <nct_id>NCT03803631</nct_id>
  </id_info>
  <brief_title>CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)</brief_title>
  <acronym>COCTAEyl</acronym>
  <official_title>CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to analyze a new noninvasive imaging examination, OCT
      angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet
      AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at baseline</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 1</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 2</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 3</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 4</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 5</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 6</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 7</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 8</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 9</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 10</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 11</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 12</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 13</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage, fibrosis and atrophy on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of fibrosis on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of atrophy on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of fibrosis on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of atrophy on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>choroidal thickness on EDI-OCT</measure>
    <time_frame>monthly during 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on SD-OCT (type 1, type 2 or mixed lesions)</measure>
    <time_frame>monthly during 13 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">49</enrollment>
  <condition>AMD</condition>
  <condition>Exudative Macular Degeneration</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with wet-AMD (NVC type 1 or 2) diagnosed maximum one week before inclusion and for
        whom Aflibercept in intra-vitreal injection technic has been prescribed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naïve patients

          -  Type 1 or type 2 Choroidal NeoVascularization (CNV)

          -  Age ≥ 55 years

          -  Presence of subfoveal CNV secondary to Age-related Macular Degeneration (AMD)

          -  At the time of inclusion, multimodal imaging should reveal exudative features

          -  Exudative AMD diagnosis established between 1 and 7 days before inclusion

          -  Monitored monthly

          -  Loading phase then bimonthly retreatment.

          -  Signed Informed Consent.

          -  Patient covered by the French Health Insurance

        Exclusion Criteria:

          -  Polypoidal choroidal vasculopathy

          -  Type 3 neovascularization

          -  Choroidal neovascularization attributable to causes other than AMD

          -  Macular hematoma

          -  Pigment epithelial detachment higher than 150µm

          -  Fibrosis &gt; 50% lesion on fundus color photography, fibroglial scar

          -  Media opacity annoying acquisition

          -  Retinal vascular occlusion

          -  Diabetic retinopathy

          -  Adult-onset foveomacular vitelliform dystrophy and other pattern dystrophies,

          -  Refractive error &gt;-6D

          -  Active intraocular inflammation in the study eye

          -  Patient who does not meet the local indication criteria for Eylea® treatment.
             Contraindications listed in the SmPCs must be taken into account

          -  Patient taking part in an interventional study at the time of enrolment.

          -  Any history of allergy to the antiseptic used during preparation of the eye for the
             IVT injection in the investigational site (e.g. povidone iodine or chlorhexidine).

          -  Pregnant and lactating women

          -  Stroke and/or myocardial infarction 3 months before inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric SOUIED</last_name>
    <phone>01 45 17 50 00</phone>
    <email>eric.souied@chicreteil.Fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camille JUNG</last_name>
    <phone>01 45 17 50 00</phone>
    <email>camille.jung@chicreteil.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Pellegrin, CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Francois KOROBELNIK</last_name>
      <phone>05 57 82 12 17</phone>
      <phone_ext>33</phone_ext>
      <email>jean-francois.korobelnik@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric SOUIED</last_name>
      <phone>01 45 17 50 00</phone>
      <phone_ext>33</phone_ext>
      <email>eric.souied@chicreteil.fr</email>
    </contact>
    <contact_backup>
      <last_name>Polina ASTROZ</last_name>
      <phone>01 45 17 50 00</phone>
      <email>polina.astroz@chicreteil.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent KODJIKIAN</last_name>
      <phone>04 72 07 17 18</phone>
      <phone_ext>33</phone_ext>
      <email>laurent.kodjikian@chu-Lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramin TADAYONI</last_name>
      <phone>01 49 95 64 86</phone>
      <phone_ext>33</phone_ext>
      <email>sec.tadayoni@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Ophtalmologique d'Imagerie et de Laser,</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salomon Yves COHEN</last_name>
      <phone>01 42 84 94 00</phone>
      <email>sycsyc75@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

